Award details

Linking recombinant gene sequence to protein product manufacturability using CHO cell genomic resources

Reference	BB/K011197/1
Principal Investigator / Supervisor	Professor David James
Co-Investigators / Co-Supervisors	Professor Mark Dickman, Dr Paul Dobson, Professor Neil Lawrence, Dr Josselin Noirel
Institution	University of Sheffield
Department	Chemical & Biological Engineering
Funding type	Research
Value (£)	654,948
Status	Completed
Type	Research Grant
Start date	30/08/2013
End date	31/05/2017
Duration	45 months

Abstract

For any engineered production process it is highly desirable to perform as much process or component design in silico as possible. This minimises trial and error testing of component interactions in the laboratory/factory. Underpinning in silico design are computational tools that can confidently be employed to predict the functional consequences of parameter change. Our previous first-round BBSRC BRIC funded grant clearly identified the importance of recombinant mRNA dynamics in controlling recombinant protein production by CHO cells. Accordingly, very recent genome-scale studies have highlighted the pre-eminence of mRNA (synthesis/stability and primarily, translational efficiency) in controlling the relative abundance of proteins in mammalian cell generally. This project is therefore concerned with the development and application of a computational design platform, necessarily derived from a combination of genome-scale datastreams, that can be reliably employed to speed the development of mammalian cell factories through the optimal design of synthetic genes with predictable in vivo performance during whole production processes. This project will also provide important tools that can be employed for a variety of genome-scale applications. By confident prediction of mRNA dynamics at the genome scale we will be able to re-create whole CHO cell proteomes in silico from high-throughput RNA sequencing data. This computational "bridge" between layers of cellular functional organisation will greatly facilitate the in silico design of synthetic genetic systems with a desired proportion of functional components and predict the relative abundance of protein components of complex cellular networks for fundamental studies of CHO cell function in the engineered environment. All proteomic and transcriptomic databases and associated computational resources will be available to the BRIC community.

Summary

Biopharmaceutical companies producing the new generation of recombinant DNA derived therapeutic proteins (e.g. cancer medicines such as Herceptin and Avastin) often use mammalian cells grown in culture to make the protein product. All production processes are based, fundamentally, upon the ability of the host mammalian cell factory to use a synthetic DNA genetic "code" to manufacture the complex protein product. This is a cornerstone of modern biotechnology. However, because protein synthesis is so complex, involving many cellular resources and machines, it is extremely difficult for genetic engineers to design a DNA code that will best enable the mammalian cell factory to operate most efficiently. Moreover, as individual mammalian cell factories can be very variable, they may differ substantially in their relative ability to make the product. As a consequence, a lot of time and money has to be spent by companies on the initial phases of the biopharmaceutical development process conducting intensive screening operations to find the best cell factory (out of a large population) able to use the genetic code it has been given. For a different protein product it is necessary to start the whole development process again. In this project we will utilise recently available high information content molecular analysis technologies and computational tools to "de-convolute" the complexity of protein synthesis in mammalian cell factories. Effectively, we know that the mammalian cell factory uses its own genetic code to make thousands of its own proteins (machines) that together perform a variety of functions that enable the cell to grow and divide. The rate at which these proteins are made varies hugely, over 1000-fold, so that the cell can make each bit of protein machinery in the right quantity to do its job. We will measure how efficiently each cellular protein is made then using advanced biological information analysis (bioinformatics) and mathematics we will determine how the cell uses pieces of information embedded in each of its genes to vary the rate at which a specific protein is made. This will enable us to create, for the first time, a usable set of "design rules" (computer programmes) that genetic engineers and cell factory developers can employ to (i) reliably design the best genetic code for any given protein product and (ii) accurately predict how much of the protein product the mammalian cell factory can make. This is important as it means that biopharmaceutical companies can design a predictable production system from scratch, enabling a more rapid transition through lengthy cell factory development processes towards (pre-)clinical trials.

Impact Summary

This research project clearly derives from (i) underpinning BRIC 1/1 research in DCJs lab which generated a fundamental understanding of the control of recombinant protein synthesis by CHO cells during production processes and (ii) a BRIC 2 Enabling Grant which was used to sequence the CHO cell genome. Based on this pre-competitive knowledge (bioscience underpinning bioprocessing) the proposed research is clearly focused on the creation of new tools and resources that would benefit a number of clearly defined user-groups: 1. UK bioindustry. This project will support UK companies developing biological medicines produced by mammalian cells in culture. We will provide our industrial partners with a data-rich resource as well as new, validated computational and informatic methods that can be implemented immediately to reduce time and costs spent in the creation of biomanufacturing systems - this represents a clear economic benefit and increased capability and competitiveness for UK bioindustry. All data and tools will be made available to BRIC partners as soon as they are generated. 2. BRIC/Bioprocessing researchers. We will produce large reference datasets and computational modelling resources (people and tools) dedicated to biomanufacturing systems. These represent a significant resource not just for industry but for any researcher engaged in pre-competitive research on CHO cell based manufacturing systems. We anticipate that adaptations of our modelling approaches could be applied to other cell factories (e.g. yeast, E. coli) or to other mammalian cell culture systems (e.g. human cell therapies etc). Development of the UKs ability to productively utilise genome-scale datasets to improve biomanufacturing systems is absolutely necessary. 3. Other researchers. This project directly address the BBSRC's 10-year vision "towards predictive biology" concentrating on a core problem for functional genomics; how to reliably predict cellular protein abundances from measured mRNA abundances. We anticipate that our research and development would be relevant to many projects utilising genome-scale transcriptomic data.

Committee	Research Committee D (Molecules, cells and industrial biotechnology)
Research Topics	Industrial Biotechnology, Synthetic Biology
Research Priority	X – Research Priority information not available
Research Initiative	Bioprocessing Research Industry Club (BRIC) [2006-2012]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search